NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free DVAX Stock Alerts $11.88 +0.42 (+3.66%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$11.40▼$11.9650-Day Range$10.73▼$12.5852-Week Range$10.48▼$15.15Volume2.28 million shsAverage Volume2.05 million shsMarket Capitalization$1.55 billionP/E Ratio198.00Dividend YieldN/APrice Target$25.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Dynavax Technologies alerts: Email Address Dynavax Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside113.2% Upside$25.33 Price TargetShort InterestBearish14.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment0.88Based on 9 Articles This WeekInsider TradingSelling Shares$262,322 Sold Last QuarterProj. Earnings Growth108.33%From $0.12 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector132nd out of 921 stocksPharmaceutical Preparations Industry46th out of 402 stocks 3.4 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDynavax Technologies has only been the subject of 2 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.99% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 3.3 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Dynavax Technologies this week, compared to 3 articles on an average week.Search Interest13 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $262,322.00 in company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 108.33% in the coming year, from $0.12 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 198.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 198.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 141.48.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyLittle-known biotech company just had groundbreaking results from a studyLearn how this company could see tremendous growth ahead with a novel broad-spectrum antiviral that has activity against RSV!Click here for the full report & ticker symbol About Dynavax Technologies Stock (NASDAQ:DVAX)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More DVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Stock News HeadlinesMay 21 at 3:52 AM | americanbankingnews.comDynavax Technologies (NASDAQ:DVAX) Upgraded by StockNews.com to "Buy"May 17, 2024 | americanbankingnews.comDynavax Technologies Co. (NASDAQ:DVAX) Short Interest Up 5.8% in AprilMay 16, 2024 | americanbankingnews.comDynavax Technologies Co. (NASDAQ:DVAX) to Post Q1 2025 Earnings of $0.03 Per Share, William Blair ForecastsMay 14, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B Regimen for Adults on Hemodialysis in the U.S.May 14, 2024 | markets.businessinsider.comHold Rating on Dynavax Amidst FDA Setback and Long-term Profitability FocusMay 14, 2024 | markets.businessinsider.comDynavax Receives FDA's CRL Regarding Four-Dose Heplisav-B Vaccine For Hemodialysis PatientsMay 14, 2024 | msn.comFDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis PatientsMay 14, 2024 | finance.yahoo.comUPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccineMay 14, 2024 | reuters.comUS FDA declines to approve expanded use of Dynavax's hepatitis B vaccineMay 14, 2024 | prnewswire.comDynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.May 13, 2024 | americanbankingnews.comDynavax Technologies Co. (NASDAQ:DVAX) to Post Q3 2024 Earnings of $0.09 Per Share, William Blair ForecastsMay 13, 2024 | americanbankingnews.comDynavax Technologies' (DVAX) Buy Rating Reaffirmed at HC WainwrightMay 11, 2024 | finance.yahoo.comAnalysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter ResultsMay 10, 2024 | finance.yahoo.comDynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...May 10, 2024 | finance.yahoo.comDynavax Technologies First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | seekingalpha.comDynavax: HEPLISAV-B Growth Up, Pipeline UncertainMay 9, 2024 | insidermonkey.comDynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 9, 2024 | fool.comDynavax Technologies (DVAX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comDynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...May 8, 2024 | investorplace.comDVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comDynavax Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | markets.businessinsider.comDynavax Technologies earnings preview: what Wall Street is expectingMay 7, 2024 | msn.comDynavax Q1 2024 Earnings PreviewApril 30, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In May 2024See More Headlines Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/22/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees408Year Founded1996Price Target and Rating Average Stock Price Target$25.33 High Stock Price Target$29.00 Low Stock Price Target$20.00 Potential Upside/Downside+113.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio198.00 Forward P/E Ratio99.00 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins3.91% Pretax Margin3.33% Return on Equity1.52% Return on Assets0.95% Debt Debt-to-Equity Ratio0.36 Current Ratio15.20 Quick Ratio14.10 Sales & Book Value Annual Sales$232.28 million Price / Sales6.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.73 per share Price / Book2.51Miscellaneous Outstanding Shares130,890,000Free Float126,991,000Market Cap$1.55 billion OptionableOptionable Beta1.30 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Ryan Spencer (Age 46)CEO, Interim CFO & Director Comp: $1.49MMr. David F. Novack (Age 62)President & COO Comp: $1.01MDr. Robert Janssen M.D. (Age 70)Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Comp: $861.52kMs. Kelly MacDonald (Age 40)Senior VP & CFO (Leave of Absence) Comp: $788.55kMr. Justin BurgessChief Accounting Officer & ControllerMr. Jeff P. Coon (Age 61)Senior VP & Chief Human Resources Officer Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsMr. John L. Slebir (Age 58)Senior VP & General Counsel Mr. Donn CasaleSenior VP & Chief Commercial OfficerDr. Dong YuSenior Vice President of Vaccine ResearchMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDIronwood PharmaceuticalsNASDAQ:IRWDInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsSwedbank ABBought 301,400 shares on 5/21/2024Ownership: 0.230%Comerica BankSold 7,169 shares on 5/17/2024Ownership: 0.035%Tidal Investments LLCBought 33,613 shares on 5/17/2024Ownership: 0.026%Walleye Trading LLCBought 100 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCSold 1,642 shares on 5/16/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions DVAX Stock Analysis - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price target for 2024? 4 brokerages have issued 1 year price targets for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $29.00. On average, they anticipate the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 113.2% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2024? Dynavax Technologies' stock was trading at $13.98 at the beginning of 2024. Since then, DVAX shares have decreased by 15.0% and is now trading at $11.88. View the best growth stocks for 2024 here. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DVAX earnings forecast. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to the consensus estimate of $77.30 million. Dynavax Technologies had a net margin of 3.91% and a trailing twelve-month return on equity of 1.52%. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. What ETFs hold Dynavax Technologies' stock? ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA) and Invesco S&P SmallCap Health Care ETF (PSCH).SPDR S&P Biotech ETF (XBI). What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.18%), Kynam Capital Management LP (3.24%), Blair William & Co. IL (1.84%), Mizuho Markets Americas LLC (0.65%), Principal Financial Group Inc. (0.59%) and Essex Investment Management Co. LLC (0.31%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DVAX) was last updated on 5/22/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsDems have chosen Biden replacement?Paradigm PressWrite this ticker symbol down…StocksToTrade$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyThis military-backed stock “owns” AI marketPorter & CompanyLittle-known biotech company just had groundbreaking results from a studySmallcaps Daily**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.